Posts tagged genes
Articles and news from the latest research reports.
Study uncovers protein key to fighting and preventing obesity
University of Florida researchers and colleagues have identified a protein that, when absent, helps the body burn fat and prevents insulin resistance and obesity. The findings from the National Institutes of Health-funded study were published online ahead of print Sunday, Jan. 6, in the journal Nature Medicine.
The discovery could aid development of drugs that not only prevent obesity, but also spur weight loss in people who are already overweight, said Dr. Stephen Hsu, one of the study’s corresponding authors and a principal investigator with the UF Sid Martin Biotechnology Development Institute.
One-third of adults and about 17 percent of children in the United States are obese, according to the Centers for Disease Control and Prevention. Although unrelated studies have shown that lifestyle changes such as choosing healthy food over junk food and increasing exercise can help reduce obesity, people are often unable to maintain these changes over time, Hsu said.
“The problem is when these studies end and the people go off the protocols, they almost always return to old habits and end up eating the same processed foods they did before and gain back the weight they lost during the study,” he said. Developing drugs that target the protein, called TRIP-Br2, and mimic its absence may allow for the prevention of obesity without relying solely on lifestyle modifications, Hsu said.
First identified by Hsu, TRIP-Br2 helps regulate how fat is stored in and released from cells. To understand its role, the researchers compared mice that lacked the gene responsible for production of the protein, with normal mice that had the gene.
They quickly discovered that mice missing the TRIP-Br2 gene did not gain weight no matter what they ate — even when placed on a high-fat diet — and were otherwise normal and healthy. On the other hand, the mice that still made TRIP-Br2 gained weight and developed associated problems such as insulin resistance, type 2 diabetes and high cholesterol when placed on a high-fat diet. The normal and fat-resistant mice ate the same amount of food, ruling out differences in food intake as a reason why the mice lacking TRIP-Br2 were leaner.
“We had to explain why the animals eating so much fat were remaining lean and not getting high cholesterol. Where was this fat going?” Hsu said. “It turns out this protein is a master regulator. It coordinates expression of a lot of genes and controls the release of the fuel form of fat and how it is metabolized.”
When functioning normally, TRIP-Br2 restricts the amount of fat that cells burn as energy. But when TRIP-Br2 is absent, a fat-burning fury seems to occur in fat cells. Although other proteins have been linked to the storage and release of fat in cells, TRIP-Br2 is unique in that it regulates how cells burn fat in a few different ways, Hsu said. When TRIP-Br2 is absent, fat cells dramatically increase the release of free fatty acids and also burn fat to produce the molecular fuel called ATP that powers mitochondria — the cell’s energy source. In addition, cells free from the influence of TRIP-Br2 start using free fatty acids to generate thermal energy, which protects the body from exposure to cold.
“TRIP-Br2 is important for the accumulation of fat,” said Dr. Rohit N. Kulkarni, also a senior author of the paper and an associate professor of medicine at Harvard Medical School and the Joslin Diabetes Center. “When an animal lacks TRIP-Br2, it can’t accumulate fat.”
Because the studies were done mostly in mice, additional studies are still needed to see if the findings translate to humans.
“We are very optimistic about the translational promise of our findings because we showed that only human subjects who had the kind of fat (visceral) that becomes insulin-resistant also had high protein levels of TRIP-Br2,” Hsu said.
“Imagine you are able to develop drugs that pharmacologically mimic the complete absence of TRIP-Br2,” Hsu said. “If a patient started off fat, he or she would burn the weight off. If people are at risk of obesity and its associated conditions, such as type 2 diabetes, it would help keep them lean regardless of how much fat they ate. That is the ideal anti-obesity drug, one that prevents obesity and helps people burn off excess weight.”
(Source: news.ufl.edu)
Risk Genes for Alzheimer’s and Mental Illness Linked to Brain Changes at Birth
Some brain changes that are found in adults with common gene variants linked to disorders such as Alzheimer’s disease, schizophrenia, and autism can also be seen in the brain scans of newborns.
“These results suggest that prenatal brain development may be a very important influence on psychiatric risk later in life,” said Rebecca C. Knickmeyer, PhD, lead author of the study and assistant professor of psychiatry in the University of North Carolina School of Medicine. The study was published by the journal Cerebral Cortex on Jan. 3, 2013.
The study included 272 infants who received MRI scans at UNC Hospitals shortly after birth. The DNA of each was tested for 10 common variations in 7 genes that have been linked to brain structure in adults. These genes have also been implicated in conditions such as schizophrenia, bipolar disorder, autism, Alzheimer’s disease, anxiety disorders and depression.
For some polymorphisms – such as a variation in the APOE gene which is associated with Alzheimer’s disease – the brain changes in infants looked very similar to brain changes found in adults with the same variants, Knickmeyer said. “This could stimulate an exciting new line of research focused on preventing onset of illness through very early intervention in at-risk individuals.”
But this was not true for every polymorphism included in the study, said John H. Gilmore, MD, senior author of the study and Thad & Alice Eure Distinguished Professor and Vice Chair for Research and Scientific Affairs in the UNC Department of Psychiatry.
For example, the study included two variants in the DISC1 gene. For one of these variants, known as rs821616, the infant brains looked very similar to the brains of adults with this variant. But there was no such similarity between infant brains and adult brains for the other variant, rs6675281.
“This suggests that the brain changes associated with this gene variant aren’t present at birth but develop later in life, perhaps during puberty,” Gilmore said.
“It’s fascinating that different variants in the same gene have such unique effects in terms of when they affect brain development,” said Knickmeyer.
Researchers uncover major source of evolutionary differences among species
University of Toronto Faculty of Medicine researchers have uncovered a genetic basis for fundamental differences between humans and other vertebrates that could also help explain why humans are susceptible to diseases not found in other species.
Scientists have wondered why vertebrate species, which look and behave very differently from one another, nevertheless share very similar repertoires of genes. For example, despite obvious physical differences, humans and chimpanzees share a nearly identical set of genes.
The team sequenced and compared the composition of hundreds of thousands of genetic messages in equivalent organs, such as brain, heart and liver, from 10 different vertebrate species, ranging from human to frog. They found that alternative splicing — a process by which a single gene can give rise to multiple proteins — has dramatically changed the structure and complexity of genetic messages during vertebrate evolution.
The results suggest that differences in the ways genetic messages are spliced have played a major role in the evolution of fundamental characteristics of species. However, the same process that makes species look different from one another could also account for differences in their disease susceptibility.
"The same genetic mechanisms responsible for a species’ identity could help scientists understand why humans are prone to certain diseases such as Alzheimer’s and particular types of cancer that are not found in other species," says Nuno Barbosa-Morais, the study’s lead author and a computational biologist in U of T Faculty of Medicine’s Donnelly Centre for Cellular and Biomolecular Research. "Our research may lead to the design of improved approaches to study and treat human diseases."
One of the team’s major findings is that the alternative splicing process is more complex in humans and other primates compared to species such as mouse, chicken and frog.
"Our observations provide new insight into the genetic basis of complexity of organs such as the human brain," says Benjamin Blencowe, Professor in U of T’s Banting and Best Department of Research and the Department of Molecular Genetics, and the study’s senior author.
"The fact that alternative splicing is very different even between closely related vertebrate species could ultimately help explain how we are unique."
Placebo and the Brain: How Does it Work?
Placebo, the positive effect of a drug that lacks any beneficial ingredients, has been researched for centuries but remain a mystery for psychologists and neuroscientists alike. Although there is now a considerable amount of amassed knowledge of how placebo can be induced, through which mechanisms it works, and which individuals are susceptible to the effect, the explicit answer to why and how our brains have the ability to ‘cure’ themselves under certain circumstances is yet to be found. Having dived into the literature on the phenomenon, a picture has emerged in which one of the brain’s greatest tricks can be better understood and the fascinating implications it has for how we look at the body-mind distinction.
What is termed a placebo is usually defined in research trying to pin down its nature as the treatment that results in a change in symptom or condition that differs from the natural course of the specific disease. Placebo effects have been shown for mainly relief of pain, but also in studies of depression, parkinson’s, and anxiety. While the sugar pill is still in use, we now know that there are a two factors that are crucial for a placebo effect to occur. These are the level of expectancy and desire to get better/not get worse that the patient feels and both are in turn sensitive to a host of psychosocial variables such as their faith in medical staff, the emotional tone of the physician-patient interaction (whether it is optimistic or pessimistic for example), memories of past experiences with the effects of medicine, and so on.
While some individuals show reliable placebo effects, others do not and the underlying causes have recently been suggested to be tied to our individual genetic makeup. Researchers from the Harvard Program for Placebo Studies found that the magnitude of the placebo effect was tied to genes coding for an anzyme that regulates the levels of dopamine in various regions of the brain. Dopamine plays a key role in processing of reward, pain, memory, and learning, all areas in which the placebo effect has been demonstrated. The study, led by Kathryn Hall, concluded that persons whose genes promote an upregulation of the levels of dopamine in the brain also exhibit the greatest placebo effects. In other studies examining release of another group of transmitters called opioids, which regulate the activity in areas that code for pain, higher amounts of opioids were matched to the size of the placebo effect found.
As for where the effect originates, research using brain imaging have found that when a real drug is compared to the effects of a placebo very similar areas show activation but some areas, such as the lateral and central prefrontal cortex, show a greater response in the placebo condition. This part of the brain is often described as overseeing and exerting control over other processing in the brain and act as a connecting point for different streams of information that build up our expectations and desires.
So, how can this knowledge about the placebo effect influence the way doctors discuss, promote, and administer their own treatments? Surely, if we know that an encouraging prognosis given together with a sugar pill can be as effective in some cases as a pharmacological product but without the side- effects, we should be using that. However, having doctors treat their patients through deception leads to obvious problems such as public mistrust in the profession. A finding from the scientists at the very same Harvard program for placebo studies might have the answer. They namely demonstrated that the placebo effect remained when participants were told explicitly that the treatment they were given was in effect useless.
Scientists in Australia and Austria have described a “network map” of genes involved in pain perception. The work, published in the journal PLOS Genetics should help identify new analgesic drugs.
Dr Greg Neely from the Garvan institute of Medical Research in Sydney and Professor Josef Penninger from the Austrian Academy of Sciences in Vienna had previously screened the 14,000 genes in the fruit fly genome and identified 580 genes associated with heat perception. In the current study, using a database from the US National Centre for Biotechnology Information, they noted roughly 400 equivalent genes in people, 35% of which are already suspected to be pain genes.
The map they constructed using fly and human data includes many known genes, as well as hundreds of new genes and pathways, and demonstrates exceptional evolutionary conservation of molecular mechanisms across species. This should not be surprising, as every creature must be able to identify a source of pain or danger in order to survive.
Comparing fly with human data, they could see that a particular kind of molecular signaling (phospholipid signaling), already implicated in pain processing, appeared in the pain network. Further, they demonstrated the importance of two enzymes that make phospholipids, by removing those enzymes from mice, making them hypersensitive to heat pain.
"Pain affects hundreds of millions of people, and is a research field badly in need of new approaches and discoveries," said Dr Neely.
"The fact that evolution has done such a remarkable job of conserving pain genes across species makes our fly data very useful, because much of it translates to rodents and people.
"We are able to test our hypotheses in mice, and if a gene or pathway or process functions as we predict, there is a good chance it will also apply to people.
"By cross-referencing fly data with human information already in the public domain — like gene expression profiling or genetic association studies — we know we’ll be able to pinpoint new therapeutic targets."
Changes in the gut bacteria protect against stroke
The human body contains ten times more bacterial cells than human cells, most of which are found in the gut. These bacteria contain an enormous number of genes in addition to our host genome, and are collectively known as the gut metagenome.
How does the metagenome affect our health? This question is currently being addressed by researchers in the rapidly expanding field of metagenomic research. Several diseases have been linked to variations in the metagenome. Researchers at Chalmers University of Technology and Gothenburg University now also show that changes in the gut metagenome can be linked to atherosclerosis and stroke.
The researchers compared a group of stroke patients with a group of healthy subjects and found major differences in their gut microbiota. In particular, they showed that genes required for the production of carotenoids were more frequently found in gut microbiota from healthy subjects. The healthy subjects also had significantly higher levels of a certain carotenoid in the blood than the stroke survivors.
Carotenoids are a type of antioxidant, and it has been claimed for many years that they protect against angina and stroke. Thus, the increased incidence of carotenoid-producing bacteria in the gut of healthy subjects may offer clues to explain how the gut metagenome affects disease states.
Carotenoids are marketed today as a dietary supplement. The market for them is huge, but clinical studies of their efficacy in protecting against angina and stroke have produced varying results. Jens Nielsen, Professor of Systems Biology at Chalmers, says that it may be preferable to take probiotics instead – for example dietary supplements containing types of bacteria that produce carotenoids.
“Our results indicate that long-term exposure to carotenoids, through production by the bacteria in the digestive system, has important health benefits. These results should make it possible to develop new probiotics. We think that the bacterial species in the probiotics would establish themselves as a permanent culture in the gut and have a long-term effect”.
“By examining the patient’s bacterial microbiota, we should also be able to develop risk prognoses for cardiovascular disease”, says Fredrik Bäckhed, Professor of Molecular Medicine at Gothenburg University. ”It should be possible to provide completely new disease-prevention options”.
'Smart' genes put us at risk of mental illness
Humans may be endowed with the ability to perform complex forms of learning, attention and function but the evolutionary process that led to this has put us at risk of mental illness.
Data from new research, published today in the journal Nature Neuroscience, was analysed by Dr Richard Emes, a bioinformatics expert from the School of Veterinary Medicine and Science at The University of Nottingham. The results showed that disease-causing mutations occur in the genes that evolved to make us smarter than our fellow animals.
Dr Emes, Director of The University of Nottingham’s Advanced Data Analysis Centre, conducted an analysis of the evolutionary history of the Discs Large homolog (Dlg) family of genes which make some of the essential building blocks of the synapse — the connection between nerve cells in the brain. He said: “This study highlights the importance of the synapse proteome — the proteins involved in the brains signalling processes — in the understanding of cognition and the power of comparative studies to investigate human disease.”
The study involved scientists from The University of Edinburgh, The Wellcome Trust Sanger Institute, the University of Aberdeen, The University of Nottingham and the University of Cambridge.
This cross-disciplinary team of experts carried out what they believe to be the first genetic dissection of the vertebrate’s ability to perform complex forms of learning, attention and function. They focussed on Dlg — a family of genes that humans shared with the ancestor of all backboned animals some 550 million years ago. Gene families like the Dlgs arose by duplication of DNA, changed by mutation over millions of years and now contribute to the complex cognitive processes we have today. However, this redundancy and subsequent accumulation of changes in the DNA may have led to increased susceptibility to some diseases.
Components of the human cognitive repertoire are routinely assessed by using computerised touch-screen methods. By using the same technique with mice researchers were able to probe the cognitive mechanisms conserved since humans and mice shared a common ancestor — around 100 million years ago. By comparing the effect of DNA changes on behavioural test outcomes this research showed a common cause of mutation and effect of learning changes in both mice and humans.
Dr Emes said: “This research shows the importance of discerning information from data and how the power of computational research combined with behavioural and cognitive studies can provide such novel insight into the basis of clinical disorders. This research provides continued support that discovery occurs at the boundary of disciplines by the integration of data.”
(Source: nottingham.ac.uk)
Origin of intelligence and mental illness linked to ancient genetic accident
Scientists have discovered for the first time how humans – and other mammals – have evolved to have intelligence. Researchers have identified the moment in history when the genes that enabled us to think and reason evolved.
This point 500 million years ago provided our ability to learn complex skills, analyse situations and have flexibility in the way in which we think. Professor Seth Grant, of the University of Edinburgh, who led the research, said: “One of the greatest scientific problems is to explain how intelligence and complex behaviours arose during evolution.”
The research, which is detailed in two papers in Nature Neuroscience, also shows a direct link between the evolution of behaviour and the origins of brain diseases. Scientists believe that the same genes that improved our mental capacity are also responsible for a number of brain disorders.
"This ground breaking work has implications for how we understand the emergence of psychiatric disorders and will offer new avenues for the development of new treatments," said John Williams, Head of Neuroscience and Mental Health at the Wellcome Trust, one of the study funders.
The study shows that intelligence in humans developed as the result of an increase in the number of brain genes in our evolutionary ancestors. The researchers suggest that a simple invertebrate animal living in the sea 500 million years ago experienced a ‘genetic accident’, which resulted in extra copies of these genes being made.
This animal’s descendants benefited from these extra genes, leading to behaviourally sophisticated vertebrates – including humans. The research team studied the mental abilities of mice and humans, using comparative tasks that involved identifying objects on touch-screen computers.
Researchers then combined results of these behavioural tests with information from the genetic codes of various species to work out when different behaviours evolved. They found that higher mental functions in humans and mice were controlled by the same genes.
Zooming in on the human brain
A visually compelling tour of the human brain, from anatomy to cells to genes and back.
Study Confirms AKT1 Genotype Contributes to Risk of Cannabis Psychosis
The ability of cannabis to produce psychosis is an important public health concern. Some studies have suggested that cannabis exposure during adolescence may increase the risk of developing schizophrenia.
For these reasons, it would be valuable if a biological test could be developed that predicted the risk of developing psychosis in people who abuse cannabis or use marijuana as a medication.
A recent study has implicated a variation in the gene that codes for a protein called RAC-alpha serine/threonine-protein kinase in the risk for cannabis psychosis. However, independent verification of these finding is critical for genetic associations with complex genetic traits, like cannabis-related psychosis, because these findings are difficult to replicate.
Dr Forti’s team carried out a case control study to investigate variation in the AKT1 gene and cannabis use in increasing the risk of psychosis.
“We studied the AKT1 gene as this is involved in dopamine signaling which is known to be abnormal in psychosis. Our sample comprised 489 patients with their first episode of psychosis and 278 healthy controls,” explained Dr Forti, who, with colleagues, reports on the results in the journal Biological Psychiatry.